Keywords: good, growth, shire, reminyl, gets, fda, boost
Good growth at Shire, Reminyl gets FDA boost
Article | 03 August 2000
Shire Pharmaceuticals has reported pretax profits (excluding charges)for the second-quarter 2000 of L27.0 million ($40.5 million), up from L20.7 million the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
